New Horizons: Finally, Approaches to Treating Moderate-to-Severe Atopic Dermatitis and Implications for Asthma

Title:

New Horizons: Finally, Approaches to Treating Moderate-to-Severe Atopic Dermatitis and Implications for Asthma

Topic: Allergy/ Immunology
Relevant Terms: Atopic Dermatitis (AD)
Primary Audience: Physicians, nurse practitioners, and physician assistants who specialize in allergy/immunology and dermatology
Launch Date: 25-Apr-17
Credits: 1.25 AMA PRA Category 1 Credits
Expiration Date: 25-Apr-18
Curriculum Name: A Self-Assessment Program on Managing Atopic Dermatitis​ and Improving Patient Outcomes

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe the pathogenesis of atopic dermatitis (AD) and the "atopic march" and discuss how the underlying pathology of the disease can be used to direct therapy
  2. Utilize current therapies and describe how to utilize emerging treatments for AD based on safety and efficacy data, pathophysiology, guidelines, individual patient needs, and sustained efficacy, especially in patients with moderate-to-severe AD
  3. Manage quality-of-life issues, psychosocial comorbidities, and treatment-related anxiety in patients with AD
  4. Engage the patient as a partner in his or her care plan to ensure best treatment adherence and outcomes

    Faculty

    Bradley E. Chipps, MD
    Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
    Sutter Medical Center
    Capital Allergy and Respiratory Disease Center
    Sacramento, CA
    Mark Boguniewicz, MD
    Professor, Division of Allergy-Immunology, Department of Pediatrics
    National Jewish Health and University of Colorado School of Medicine
    Denver, CO
    Jonathan Silverberg, MD, PhD, MPH
    Assistant Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
    Northwestern University Feinberg School of Medicine
    Director, Northwestern Medicine
    Multidisciplinary Eczema Center
    Director, Patch Testing Clinic
    Northwestern Memorial Hospital
    Chicago, IL
    Linda Stein Gold, MD
    Director, Dermatology Clinical Research
    Division Head, Dermatology
    Henry Ford Health System
    Detroit, MI
    Physician Continuing Medical Education
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, and Novartis (Consulting Fees).​
    • Mark Boguniewicz, MD, has affiliations with Celgene and Regeneron (Consulting Fees); and Anacor (Research Grants).
    • Jonathan Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anacor, Eli Lilly, GlaxoSmithKline (GSK), MedImmune, Procter & Gamble, Pfizer, PuriCore, and Regeneron-Sanofi (Consulting Fees); and AbbVie, Celgene, Eli Lilly, GSK, Regeneron-Sanofi, and Roche (Investigator in Clinical Trials).
    • Linda Stein Gold, MD, has affiliations with Allergan, Celgene, Galderma, Leo, Medimetriks, Novartis, Otsuka, Pfizer, and Valeant (Consulting Fees); Allergan, Celgene, Galderma, GSK, Leo, Novartis, and Valeant (Contracted Research); and Allergan, Celgene, Galderma, Leo, Medimetriks, Novartis, and Valeant (Fees for Non-CME/CE Services); and Roche (Medical/Legal Consulting).
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    RMEI Medical Education, LLC
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
    • Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
    • Elizabeth Paczolt, MD, has no affiliations with commercial interests to disclose.
    • Amy Reeve has no affiliations with commercial interests to disclose.
    Planners and Managers
    The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
     
    Media
    Internet
     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
     
    Fee Information
    There is no fee for this educational activity.
     
    Statement of Commercial Support
    This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an independent medical educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.
     
    How to Receive Credit
    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.
    Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
     
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.